External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ERA 2026

We will be contributing to topics related to
-
08:33 AM
Duration 6mins Glasgow, UK
Correlating Matched First Morning Void And 24-Hour Urine Protein-To-Creatinine Ratios: An Exploratory Analysis of the REGENCY trial
Rachel Jones, Brad H. Rovin, Elsa Martins, Jay Garg, Liz Lightstone, Brian Rayner, Gustavo Aroca-Martínez, Bongin Yoo, Theodore A. Omachi, Thomas Schindler, William F. Pendergraft, Ana Malvar
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 AM
Duration 6mins Glasgow, UK
Obinutuzumab Promotes Early Kidney Tubular Repair and Regeneration in Lupus Nephritis: REGENCY Post hoc Analyses of Urine Epidermal Growth Factor
Brad H. Rovin, Rachel Jones, Holly J. Clarke, Ben Lanza, Theodore A. Omachi, William F. Pendergraft III, Harini Raghu, Juan M. Mejia-Vilet
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:10 AM
Duration 15mins Glasgow, UK
Efficacy and Safety of Obinutuzumab Compared with Tacrolimus in Primary Membranous Nephropathy: Topline Results of the Phase III MAJESTY Trial
Fernando Fervenza, Chuanming Hao, Gianna Kirsztajn, Loreto Gesualdo, Tomasz Hryszko, Antonio Pisani, Dario Roccatello, Jay Garg, Thomas Schindler, Sunny Pokala, Eriola Berisha, Ana Malvar
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon